Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Brain Neoplasms 2Respiratory Tract Diseases 1Neoplasms 1Meningeal Carcinomatosis 1

Interventions

Carboplatin 171Paclitaxel 129Radiotherapy 119Cisplatin 109Docetaxel 93Gemcitabine 81Erlotinib Hydrochloride 80Pemetrexed 78Bevacizumab 56Etoposide 41pembrolizumab 36Gefitinib 32Vinorelbine 31Topotecan 30Surveys and Questionnaires 29Irinotecan 28Radiosurgery 21Nivolumab 20Drug Therapy 20Magnetic Resonance Spectroscopy 18Cetuximab 18durvalumab 17Early Intervention, Educational 17Blood Specimen Collection 17Surgical Procedures, Operative 16Cyclophosphamide 16Celecoxib 15Ipilimumab 14Immunohistochemistry 14Filgrastim 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lung Neoplasms × AZD3759 × Clear all
NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed
492 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT03360929 2022-11-25

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

LYZZ Alpha Holding Ltd

Phase 1/2 Completed
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡